ArticlePloS one2025
Safety of íntravitreal panitumumab combined with intravitreal ranibizumab in rabbits.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the safety of intravitreally applied epidermal growth factor (EGF) receptor antibody panitumumab combined with intravitreally injected vascular endothelial growth factor (VEGF) antibody ranibizumab in rabbits.
methodsThe experimental study included 8 male rabbits (age: 2-3 months; weight: 2.5-2.6 kg). The right eyes received three intravitreal injections of panitumumab (1 mg in 0.10 mL) combined with intravitreal injections of ranibizumab (0.5 mg in 0.05 mL) in intervals of 4 weeks, while the left eyes received three double intravitreal injections of Ringer´s solution (0.10 mL and 0.05mL). At baseline, at the time points of the re-injections, and at 2 weeks and at 6 weeks after the last injection, the animals were examined by fundus photography and optical coherence tomography (OCT). At study end at 2 weeks after the last injection for 4 animals (total study duration: 10 weeks) or at 6 weeks after the last injection for the remaining 4 rabbits (total study duration: 14 weeks), the animals were sacrificed and the eyes were histomorphometrically examined.
resultsThe right eyes (study eyes) and left eyes (control eyes) did not differ significantly in cell count of the retinal ganglion cell layer (8.5 ± 8.3 cells per 150µm versus 4.5 ± 3.3 cells;P = 0.04), inner nuclear layer (33.1 ± 14.0 cells versus 49.0 ± 22.3 cells;P = 0.04) and outer nuclear layer (133.7 ± 50.0 cells versus 171.3 ± 75.3 cells;P = 0.07) nor in mean thickness of the ganglion cell layer (31.8 ± 34.4µm versus 24.3 ± 15.2µm;P = 0.15), inner plexiform layer (32.4 ± 48.2µm versus 25.6 ± 11.2µm;P = 0.22), inner nuclear layer (26.6 ± 14.0µm versus 26.7 ± 10.2µm;P = 0.43), outer plexiform layer (6.6 ± 3.7µm versus 6.8 ± 2.0µm;P = 0.07), outer nuclear layer (32.6 ± 16.1µm versus 30.6 ± 11.8 µm;P = 0.82) and of total retina (157.7 ± 99.4µm versus 152.0 ± 60.7µm;P = 0.34). Apoptotic cells were not detected in either group. Mean IOP did not differ significantly between the right eyes (study eyes) and the left eyes (control eyes). Intravital signs of intraocular toxicity were not detected.
conclusionsRepeatedly intraocularly applied panitumumab combined with ranibizumab was intraocularly well tolerated and did not differ in the ocular reaction from intravitreal injections of Ringer´s solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.